Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress

The proteasome inhibitor bortezomib has proven to be invaluable in the treatment of myeloma. By exploiting the inherent high immunoglobulin protein production of malignant plasma cells, bortezomib induces endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), resulting in myeloma...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Wallington-Beddoe, Craig T., Bennett, Melissa K., Vandyke, Kate, Davies, Lorena, Zebol, Julia R., Moretti, Paul A.B., Pitman, Melissa R., Hewett, Duncan R., Zannettino, Andrew C.W., Pitson, Stuart M
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Priority Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546428/
https://ncbi.nlm.nih.gov/pubmed/28467788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17115
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi